Urinary incontinence in women the management of urinary incontinence in women
New and updated recommendations have been included based on evidence of the clinical and cost effectiveness of: Antimuscarinic drugs: darifenacin, darifenacin - extended release, fesoterodine - modified release, oxybutinin, oxybutynin - modified release, oxybutynin - transdermal, oxybutynin - topica...
| Corporate Authors: | , , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
London
Royal College of Obstetricians and Gynaecologists
2013, September 2013
|
| Edition: | Second edition |
| Series: | NICE clinical guidelines
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | New and updated recommendations have been included based on evidence of the clinical and cost effectiveness of: Antimuscarinic drugs: darifenacin, darifenacin - extended release, fesoterodine - modified release, oxybutinin, oxybutynin - modified release, oxybutynin - transdermal, oxybutynin - topical gel, propiverine, propiverine - extended release, solifenacin, tolterodine, tolterodine - extended release, trospium, trospium - extended release; Percutaneous sacral nerve stimulation (P-SNS) compared with either no active treatment or placebo; Percutaneous posterior tibial nerve stimulation (P-PTNS) compared with either no active treatment or placebo; Transcutaneous posterior tibial nerve stimulation (T-PTNS) compared with either no active treatment or placebo; Transcutaneous sacral nerve stimulation (T-SNS) compared with either no active treatment or placebo; A comparison of T-SNS, This guidance is a partial update of National Institute for Health and Care Excellence (NICE) clinical guideline 40 (published October 2006) and will replace it. T-PTNS and P-PTNS (if these treatments are found to be effective compared with no treatment or placebo); Botulinum toxin A compared with placebo in women with overactive bladder (OAB) caused by detrusor overactivity; Pharmacological treatment compared with neuromodulation in all women with overactive bladder; Pharmacological treatment compared with neuromodulation and botulinum toxin A in women with OAB caused by detrusor overactivity only; Surgical approaches for mid-urethral procedures in women undergoing their primary surgical tape procedure: retropubic bottom up, retropubic top down, transobturator inside out, transobturator outside in, single incision; Interventions for women for whom the primary tape procedure has failed: conservative management, looking only at: lifestyle interventions, specifically weight loss, fluid management and smoking cessation and physical therapy, specifically pelvic floor muscle training, repeat tape procedure, fascial sling, colposuspension |
|---|---|
| Item Description: | Title from PDF title page. - This guidance is a partial update of National Institute for Health and Care Excellence (NICE) clinical guideline 40 (published October 2006) and will replace it.-- P. 2. - Replacement of: Urinary incontinence / National Collaborating Centre for Women's and Children's Health ; commissioned by the National Institute for Health and Clinical Excellence. London : RCOG Press, 2006 |
| Physical Description: | 1 PDF file (iv, 385 pages) illustrations |